| A | Ampere |
| A (in chemical element symbol) |
Mass Number |
| A7R | Ala-Thr-Trp-Leu-Pro-Pro-Arg |
| AAZTA | 2,2-((1,4-Bis(carboxymethyl)-1,4-diazepan-6-yl)azanediyl)diacetic Acid |
| Ah | Ampere-hour |
| BN | Bombesin |
| Bq | Becquerel |
| cRGD | Cyclic Arginylglycylaspartic Acid |
| CT | Computed Tomography |
| D | Deuteron |
| DGA | Diglycolamide |
| DO3AM-NI | 2,2′,2″-(10-(2-((2-(2-Nitro-1H-imidazol-1-yl)ethyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DO3AP | 2,2′,2″-(10-(Phosphonomethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DO3APABn | 2,2′,2″-(10-(((4-Aminobenzyl)(hydroxy)phosphoryl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DO3APPrA | 2,2′,2″-(10-(((2-Carboxyethyl)(hydroxy)phosphoryl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DOTA | 2,2′,2″,2‴-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic Acid |
| DOTA-NOC | 2,2′,2″-(10-(2-((1-((13-((1H-Indol-3-yl)methyl)-10-(4-aminobutyl)-4-((1,3-dihydroxybutan-2-yl)carbamoyl)-7-(1-hydroxyethyl)-16-(naphthalen-1-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DOTA-PSMA-617 | ((1-Carboxy-5-(3-(naphthalen-2-yl)-2-(4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)glutamic Acid |
| DOTA-RGD | 2,2′,2″-(10-(2-((4-(14-Benzyl-11-(carboxymethyl)-5-(3-guanidinopropyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butyl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DOTATOC | 2,2′,2″-(10-(2-((1-((13-((1H-Indol-3-yl)methyl)-10-(4-aminobutyl)-4-((1,3-dihydroxybutan-2-yl)carbamoyl)-16-(4-hydroxybenzyl)-7-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic Acid |
| DR7A | DArg-DPro-DPro-DLeu-DTrp-DThr-DAla |
| DTPA | 2,2′,2″,2‴-((((Carboxymethyl)azanediyl)bis(ethane-2,1-diyl))bis(azanetriyl))tetraacetic Acid |
| E | Energy of an Incident Photon in a Scintillator |
| e− | Electron |
| e+ | Positron |
| EDTA | 2,2′,2″,2‴-(Ethane-1,2-diylbis(azanetriyl))tetraacetic Acid |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| eV | Electron Volt |
| FISRE | Free-Ion Selective Radiotracer Extraction |
| g | Ground State |
| GRPR | Gastrin Releasing Peptide Receptors |
| H3mpatcn | 2,2′-(7-((6-Carboxypyridin-2-yl)methyl)-1,4,7-triazonane-1,4-diyl)diacetic Acid |
| H3NOTA | 1,4,7-Triazacyclononane-1,4,7-triacetic Acid |
| H4pypa | 6,6′-(((Pyridine-2,6-diylbis(methylene))bis((carboxymethyl)azanediyl))bis(methylene))dipicolinic Acid |
| HDEHP | Di-2-ethylhexyl Phosphoric Acid |
| HFIR | High Flux Isotope Reactor |
| HPGe | High-Purity Germanium |
| HPLC | High Performance Liquid Chromatography |
| ID/g | Injected Dose per Gram of Radionuclide |
| iTLC | Instant Thin-Layer Chromatography |
| K4R | Lys(HArg)-Dab-Pro-Arg |
| LNCaP | Human Prostate Cancer Cell Line |
| log K | Stability Constant |
| log Ki | Protonation Constant |
| m | Metastable State |
| MBq/μmol | Megabecquerel per Micromole or Apparent Molar Activity |
| MCi | Millicurie |
| MP-AES | Microwave Plasma-Atomic Emission Spectrometry |
| MRI | Magnetic Resonance Imaging |
| N | Number of Neutrons |
| nat-V | Natural Vanadium |
| NBD | 2,2′,2″,2‴-(2-(4-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic Acid |
| NI | 2-Nitroimidazole |
| NODAGA-NOC | 2,2′-(7-(4-((1-((13-((1H-Indol-3-yl)methyl)-10-(4-aminobutyl)-4-((1,3-dihydroxybutan-2-yl)carbamoyl)-7-(1-hydroxyethyl)-16-(naphthalen-1-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-1-oxo-3-phenylpropan-2-yl)amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic Acid |
| NODAGA-RGD | 2,2-(7-(1-Carboxy-4-((4-(11-(carboxymethyl)-5-(3-guanidinopropyl)-14-(4-hydroxybenzyl)-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaazacyclopentadecan-2-yl)butyl)amino)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic Acid |
| NOTA | 2,2′,2″-(1,4,7-Triazonane-1,4,7-triyl)triacetic Acid |
| NRP-1 protein | Neuropilin-1 Protein |
| p | Proton |
| PC-3 cells | Prostate Cancer cells |
| PET | Positron Emission Tomography |
| picagaDUPA | 17-(4-(Carboxymethyl)-7-((6-carboxypyridin-2-yl)methyl)-1,4,7-triazonan-1-yl)-5,10,14-trioxo-4,6,11,13-tetraazaheptadecane-1,3,7,17-tetracarboxylic Acid |
| PSI | Paul Scherrer Institute |
| PSMA | Prostate-Specific Membrane Antigen |
| PTFE | Polytetrafluoroethylene |
| RGD | Arg-Gly-Asp or Arginylglycylaspartic Acid |
| s | Seconds |
| SCID | Severe Combined Immunodeficiency Disease |
| SCX | Strong Cation Exchange |
| SEM | Scanning Electron Microscopy |
| SiPM | Silicon Photomultiplier |
| SPECT | Single-Photon Emission Computed Tomography |
| SPION | Super-Paramagnetic Iron Oxide Nanoparticles |
| t1/2 | Half-life |
| TBP | Tributyl Phosphate |
| TEM | Transmission Electron Microscopy |
| TETA | 2,2′,2″,2‴-(1,4,8,11-Tetraazacyclotetradecane-1,4,8,11-tetrayl)tetraacetic Acid |
| TLC | Thin-Layer Chromatography |
| UTEVA | Uranium and Tetravalent Actinide |
| UV | Ultraviolet |
| V/M | Volume-to-Muscle ratio |
| VECC | Variable Energy Cyclotron Center |
| x | Alpha or Beta Particle |
| X | Position of an Incident Photon in a Scintillator on X-Axis |
| X (in nuclear decay reactions) | Parent Nucleus |
| X* | Excited Nuclear State of Parent Nucleus |
| Y | Position of an Incident Photon in a Scintillator on Y-Axis |
| Υ (in nuclear decay reactions) | Daughter Nucleus |
| y | Years |
| Z | Atomic Number |
| α | Alpha Particle |
| β | Beta Particle |
| β+ | Positron |
| γ | Gamma Radiation |
| μL | Microliters |